Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01335464
Registration number
NCT01335464
Ethics application status
Date submitted
13/04/2011
Date registered
14/04/2011
Date last updated
25/07/2016
Titles & IDs
Public title
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
Query!
Scientific title
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Query!
Secondary ID [1]
0
0
2010-024251-87
Query!
Secondary ID [2]
0
0
1199.32
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - placebo
Treatment: Drugs - BIBF 1120
Experimental: BIBF 1120 - patient receives capsules containing BIBF 1120 twice a day
Placebo Comparator: placebo - patient receives capsules identical to those containing active drug
Treatment: Drugs: placebo
placebo matching BIBF1120, BID
Treatment: Drugs: BIBF 1120
BIBF1120 BID (twice daily)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
Query!
Assessment method [1]
0
0
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate
Query!
Timepoint [1]
0
0
52 weeks
Query!
Secondary outcome [1]
0
0
Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
Query!
Assessment method [1]
0
0
This is a key secondary endpoint.
SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [1]
0
0
baseline and 52 weeks
Query!
Secondary outcome [2]
0
0
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Query!
Assessment method [2]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
Unexplained worsening or development of dyspnoea within 30 days
New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit
Exclusion of infection as per routine clinical practice and microbiological studies
Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .
Query!
Timepoint [2]
0
0
52 weeks
Query!
Secondary outcome [3]
0
0
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Query!
Assessment method [3]
0
0
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [3]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [4]
0
0
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Query!
Assessment method [4]
0
0
Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [4]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [5]
0
0
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Query!
Assessment method [5]
0
0
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [5]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [6]
0
0
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Query!
Assessment method [6]
0
0
Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [6]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [7]
0
0
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
Query!
Assessment method [7]
0
0
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within =5%).
Query!
Timepoint [7]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [8]
0
0
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
Query!
Assessment method [8]
0
0
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by >10%, and change within =10%)
Query!
Timepoint [8]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [9]
0
0
FVC Responders Using 10% Threshold at 52 Weeks
Query!
Assessment method [9]
0
0
FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
Query!
Timepoint [9]
0
0
52 weeks
Query!
Secondary outcome [10]
0
0
Proportion of FVC Responders Using 5% Threshold at 52 Weeks
Query!
Assessment method [10]
0
0
Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
Query!
Timepoint [10]
0
0
52 weeks
Query!
Secondary outcome [11]
0
0
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [11]
0
0
Proportion of SGRQ responders at 52 weeks
Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks.
Query!
Timepoint [11]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [12]
0
0
Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [12]
0
0
SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [12]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [13]
0
0
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [13]
0
0
SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [13]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [14]
0
0
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [14]
0
0
SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [14]
0
0
baseline and 52 weeks
Query!
Secondary outcome [15]
0
0
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Query!
Assessment method [15]
0
0
SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
Query!
Timepoint [15]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [16]
0
0
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [16]
0
0
Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [16]
0
0
baseline and 52 weeks
Query!
Secondary outcome [17]
0
0
Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [17]
0
0
The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [17]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [18]
0
0
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks : Patient Reported Outcomes (PROs)
Query!
Assessment method [18]
0
0
The cough domains of the Cough and Sputum Assessment Questionnaire (CASA-Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Query!
Timepoint [18]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [19]
0
0
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Query!
Assessment method [19]
0
0
Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
Query!
Timepoint [19]
0
0
52 weeks
Query!
Secondary outcome [20]
0
0
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
Query!
Assessment method [20]
0
0
The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
Query!
Timepoint [20]
0
0
baseline, 12 weeks, 24 weeks and 52 weeks
Query!
Secondary outcome [21]
0
0
Risk of an Acute IPF Exacerbation Over 52 Weeks
Query!
Assessment method [21]
0
0
The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100)
Query!
Timepoint [21]
0
0
52 weeks
Query!
Secondary outcome [22]
0
0
Time to Death Over 52 Weeks
Query!
Assessment method [22]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period) .
Query!
Timepoint [22]
0
0
52 weeks
Query!
Secondary outcome [23]
0
0
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
Query!
Assessment method [23]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).
Query!
Timepoint [23]
0
0
52 weeks
Query!
Secondary outcome [24]
0
0
Time to On-treatment Death
Query!
Assessment method [24]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.
Query!
Timepoint [24]
0
0
52 weeks
Query!
Secondary outcome [25]
0
0
Time to Death or Lung Transplant Over 52 Weeks
Query!
Assessment method [25]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).
Query!
Timepoint [25]
0
0
52 weeks
Query!
Secondary outcome [26]
0
0
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
Query!
Assessment method [26]
0
0
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
Query!
Timepoint [26]
0
0
52 weeks
Query!
Secondary outcome [27]
0
0
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
Query!
Assessment method [27]
0
0
Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
Query!
Timepoint [27]
0
0
Baseline and 52 weeks
Query!
Secondary outcome [28]
0
0
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
Query!
Assessment method [28]
0
0
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Query!
Timepoint [28]
0
0
Baseline and 52 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
1. Age >= 40 years;
2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European
Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic
Association (ALAT) IPF guideline for diagnosis and management, within 5 years;
3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if
available surgical lung biopsy pattern, as assessed by central reviewers, are
consistent with diagnosis of IPF
4. Dlco (corrected for Hb): 30%-79% predicted of normal;
5. FVC>= 50% predicted of normal
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
1. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit
of Normal (ULN)
2. Bilirubin > 1.5 x ULN;
3. Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);
4. Patient likely to have lung transplantation during study (being on transplantation
list is acceptable for participation);
5. Myocardial infarction within 6 months;
6. Unstable angina within 1 month;
7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic
anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event
within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or
ulcers or major injury or surgery within 3 months);
8. Thrombotic risk (inherited predisposition; history of thrombotic event (including
stroke and transient ischemic attacks) within 12 months;
9. International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and
partial thromboplastin time (PTT) by > 50% of institutional ULN);
10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit
1;
11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of
visit 1;
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/10/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
515
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
1199.32.61001 Boehringer Ingelheim Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
1199.32.61002 Boehringer Ingelheim Investigational Site - Concord
Query!
Recruitment hospital [3]
0
0
1199.32.61003 Boehringer Ingelheim Investigational Site - Daw Park
Query!
Recruitment hospital [4]
0
0
1199.32.61005 Boehringer Ingelheim Investigational Site - Frankston
Query!
Recruitment hospital [5]
0
0
1199.32.61004 Boehringer Ingelheim Investigational Site - Prahran
Query!
Recruitment postcode(s) [1]
0
0
- Camperdown
Query!
Recruitment postcode(s) [2]
0
0
- Concord
Query!
Recruitment postcode(s) [3]
0
0
- Daw Park
Query!
Recruitment postcode(s) [4]
0
0
- Frankston
Query!
Recruitment postcode(s) [5]
0
0
- Prahran
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Delaware
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Iowa
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kansas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Minnesota
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Jersey
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Oregon
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Rhode Island
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Virginia
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Washington
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Bruxelles
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Jette
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Yvoir
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Beijing
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Changsha
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Chengdu
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Nanchang
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Xi'An
Query!
Country [29]
0
0
Czech Republic
Query!
State/province [29]
0
0
Prague 4
Query!
Country [30]
0
0
Czech Republic
Query!
State/province [30]
0
0
Prague 8
Query!
Country [31]
0
0
Czech Republic
Query!
State/province [31]
0
0
Usti nad Labem
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Bobigny
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Nice Cedex 1
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Paris Cedex 15
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Paris Cedex 18
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris cedex 20
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Reims cedex
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Rennes Cedex 9
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Bamberg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Donaustauf
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Essen
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Freiburg/Breisgau
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Gießen
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Großhansdorf
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Heidelberg
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Mainz
Query!
Country [47]
0
0
India
Query!
State/province [47]
0
0
Ahmedabad
Query!
Country [48]
0
0
India
Query!
State/province [48]
0
0
Coimbatore
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
Jaipur
Query!
Country [50]
0
0
India
Query!
State/province [50]
0
0
Kolkatta
Query!
Country [51]
0
0
India
Query!
State/province [51]
0
0
Mumbai
Query!
Country [52]
0
0
Ireland
Query!
State/province [52]
0
0
Dublin
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Haifa
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Petah Tiqwa
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Rehovot
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Catania
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Chieti Scalo
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Forli'
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Milano
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Modena
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Monza
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Napoli
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Padova
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Pisa
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Roma
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Siena
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Bunkyo-ku,Tokyo
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Kiyose, Tokyo
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Kumagaya, Saitama
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Minato-ku, Tokyo
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Naka-gun, Ibaraki
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Ota-ku, Tokyo
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Sendai, Miyagi
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Shibuya-ku, Tokyo
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Shimotsuke,Tochigi
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Shinjuku-ku, Tokyo
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Yokohama, Kanagawa
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Aberdeen
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Birmingham
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Leeds
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Liverpool
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
London
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Oxford
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Westbury on Trym
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in
scarring of the lung and there is a high unmet medical need for effective treatment to halt
lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the
death rate.
In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of
treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of
patients treated with high dose of BIBF 1120 compared to placebo.
Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of
BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will
be conducted as a prospective, randomised design with the aim to collect safety and efficacy
data.
Respiratory function is globally accepted for assessment of treatment effects in IPF
patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is
part of the usual examinations done in IPF patients.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01335464
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01335464
Download to PDF